TMDX NASDAQ
Credit Risk of going bust: higher than 61% of companies Debt: 26.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $1.76 (down 98%), TransMedics Group, Inc. would be worth roughly what it owes.
Total debt $867.7M against a stock market value of $2.45B.
Distance to default 4.18 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $270.6M (short-term plus half of long-term), stock volatility 58.4%; Altman Z 2.43. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Andover, MA 01810
US
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Araujo Fernando N. | 0 | — | 2026-09-21 | |
| Weill David | P-Purchase | 1,336 | $81.63 | 2026-09-11 |
| TOBIN JAMES R | G-Gift | 18,000 | — | 2026-08-17 |
| Hassanein Waleed H | A-Award | 49,669 | — | 2026-07-10 |
| Hassanein Waleed H | A-Award | 112,984 | $71.23 | 2026-07-10 |